Skip to content

Effects of Astragalus Membranaceus on Muscle Function

Astragalus Membranaceus Modulates Inflammatory Markers Without Enhancing Muscle Function Following Intensified Resistance Training

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07552675
Acronym
AD ASTRA
Enrollment
24
Registered
2026-04-27
Start date
2023-09-01
Completion date
2026-02-25
Last updated
2026-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Adult

Keywords

Dietary supplementation, inflammation, muscle damage, force, non-functional overreaching

Brief summary

This study evaluated whether daily supplementation with Astragali radix extract (480 mg/day) for 10 weeks could attenuate training-induced impairments in muscle function, joint pain, and inflammatory markers in moderately active young adults undergoing a structured resistance training program. Participants were randomized in a double-blind, placebo-controlled design to receive either Astragali radix extract (ASTRA) or placebo (PLA) during 8 weeks of progressive resistance training followed by 2 weeks of intensified training. The primary outcome was maximal voluntary isometric torque (MVIT) of the knee extensors. Secondary outcomes included one-repetition maximum (1RM) strength, knee range of motion, muscle soreness (VAS), and circulating blood biomarkers of muscle damage and inflammation.

Detailed description

Background and Rationale Physical inactivity is associated with approximately 10% of premature deaths and an estimated €100 billion in annual healthcare costs. Current guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week alongside resistance training for optimal health. However, when the balance between training load and recovery is disturbed, athletes may develop non-functional overreaching (NFOR), a state of maladaptation characterized by adverse physiological, psychological, and functional outcomes requiring days to weeks for full resolution. Astragali radix (Astragalus membranaceus), belonging to the Fabaceae family and officially included in the European Pharmacopoeia (8th ed.), is a traditional Chinese herbal medicine known for its antioxidant, anti-inflammatory, and immunomodulatory properties. Prior research has suggested potential benefits in reducing post-exercise inflammatory markers and improving aerobic performance, but its effects during prolonged, structured resistance training programs had not been systematically investigated. Study Design This was a randomized, double-blind, placebo-controlled trial with 1:1 allocation. Twenty-four moderately active healthy young adults (mean age \ 25 years; 13 males/11 females across groups) were enrolled after initial screening of 72 volunteers. Participants were randomly allocated to the ASTRA group (n=13) or PLA group (n=11). Randomization was performed using a computer-generated sequence. Interventions Participants in the ASTRA group received 480 mg/day of Astragali radix hydroalcoholic extract (Axtragyl®, Giellepi S.p.A., Seregno, Italy; 2 capsules × 240 mg/day) for 10 weeks. The PLA group received matched capsules containing inert substances (microcrystalline cellulose, maltodextrin, magnesium salts of fatty acids) for the same period. Supplement compliance was monitored via daily text messages and collection of returned empty containers. Training Protocol All participants performed a combined training intervention consisting of: (1) 8 weeks of regular resistance training (RT) at 3 sessions/week, with progressive overload targeting lower limb muscles (back squat, leg press, single-leg extension, single-leg curl, calf raises) at 70-80% of 1RM; followed by (2) 2 weeks of intensified training (IT) at 6 sessions/week, performing 10 sets of 1 repetition at 100% 1RM of leg press and leg extension. All sessions were supervised by experienced personnel. Assessments Testing was performed at three time points: baseline (BAS, one week before intervention), after 8 weeks of RT (48 hours post-last session), and after IT completion (24 hours post-last session). Assessments included: Maximal voluntary isometric torque (MVIT) of knee extensors measured on a custom-built ergometer (primary outcome) 1RM of leg press and leg extension Knee range of motion (ROM) assessed by gyroscope-based goniometry during passive movement Muscle soreness via 100-mm visual analogue scale (VAS) Blood biomarkers: serum CPK, LDH, myoglobin, CRP, IL-6, TNF-α, IGF-1, cortisol, and testosterone (venous blood drawn at BAS, RT, and IT under standardized fasting conditions) Statistical Analysis A general linear model for repeated measures was used, with time (BAS, RT, IT) as within-subject factor and supplementation group (ASTRA vs. PLA) as between-subject factor. Post-hoc comparisons used Bonferroni correction. Effect sizes were reported as partial eta squared (η²). Statistical significance was set at p \< 0.05.

Interventions

DIETARY_SUPPLEMENTAstragalus Membranaceus

480 mg daily of astragali radix extract for 10 weeks (2 capsules x day orally).

DIETARY_SUPPLEMENTPlacebo

Capsules containing an inert substance identical by visual, taste, and smell to the active formulation but without any active ingredients

Sponsors

University of Pavia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

* Physical Activity Status: Moderately active, defined as a metabolic equivalent (MET) between 3 and 6 based on the International Physical Activity Questionnaire - Short Form (IPAQ-SF) (Bull et al., 2020). * Health Status: Non-smokers and free from cardiovascular, metabolic, and neurological diseases.

Exclusion criteria

* Injuries: any muscular, bone, or joint injuries sustained within the 6 months prior to the study. * Supplementation/Medication: A history of consuming dietary supplements or drugs within the 6 months preceding the intervention.

Design outcomes

Primary

MeasureTime frameDescription
MVITOne week before the start of the intervention (BAS), 48 hours after RT phase, and 24 hours following the completion of IT phase.Maximal voluntary isometric torque

Secondary

MeasureTime frameDescription
ROMOne week before the start of the intervention (BAS), 48 hours after RT phase, and 24 hours following the completion of IT phaseRange of Motion
Muscle sorenessOne week before the start of the intervention (BAS), 48 hours after RT phase, and 24 hours following the completion of IT phase.Subjects were asked to mark their pain level on the line under the supervision of the examiner while the knee joint was passively flexed and extended by the investigator.
Serum Creatine PhosphokinaseOne week before the start of the intervention (BAS), 48 hours after RT phase, and 24 hours following the completion of IT phase.Serum Creatine Phosphokinase
Interleukin-6 (IL-6)One week before the start of the intervention (BAS), 48 hours after RT phase, and 24 hours following the completion of IT phase.Interleukin-6 (IL-6)
Tumor necrosis factor-alpha (TNF-α)One week before the start of the intervention (BAS), 48 hours after RT phase, and 24 hours following the completion of IT phase.Tumor necrosis factor-alpha (TNF-α)

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 1, 2026